Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer
1
Takeda San Diego, San Diego, CA 92121, USA.
|
Publication type: Journal Article
Publication date: 2011-03-01
scimago Q2
wos Q2
SJR: 0.472
CiteScore: 5.1
Impact factor: 2.2
ISSN: 0960894X, 14643405
PubMed ID:
21310613
Organic Chemistry
Drug Discovery
Biochemistry
Molecular Biology
Pharmaceutical Science
Clinical Biochemistry
Molecular Medicine
Abstract
A novel 5-phenylamino-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione series of MEK inhibitors has been developed using structure-based drug design. Lead optimization of this series led to the discovery of TAK-733. This was advanced to Phase I clinical studies for cancer treatment.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
3
|
|
|
Molecules
3 publications, 2.91%
|
|
|
International Journal of Molecular Sciences
3 publications, 2.91%
|
|
|
Bioorganic and Medicinal Chemistry Letters
3 publications, 2.91%
|
|
|
Bioorganic and Medicinal Chemistry
3 publications, 2.91%
|
|
|
Oncotarget
2 publications, 1.94%
|
|
|
Scientific Reports
2 publications, 1.94%
|
|
|
Molecular Cancer
2 publications, 1.94%
|
|
|
European Journal of Medicinal Chemistry
2 publications, 1.94%
|
|
|
Pharmacological Research
2 publications, 1.94%
|
|
|
Chemical Biology and Drug Design
2 publications, 1.94%
|
|
|
ACS Chemical Biology
2 publications, 1.94%
|
|
|
ACS Chemical Neuroscience
2 publications, 1.94%
|
|
|
Organic and Biomolecular Chemistry
2 publications, 1.94%
|
|
|
Expert Opinion on Therapeutic Targets
2 publications, 1.94%
|
|
|
Expert Opinion on Investigational Drugs
2 publications, 1.94%
|
|
|
Expert Opinion on Therapeutic Patents
2 publications, 1.94%
|
|
|
Molecular Cancer Therapeutics
2 publications, 1.94%
|
|
|
Cancer Discovery
2 publications, 1.94%
|
|
|
Mini-Reviews in Medicinal Chemistry
1 publication, 0.97%
|
|
|
Future Oncology
1 publication, 0.97%
|
|
|
Genes and Cancer
1 publication, 0.97%
|
|
|
Clinical Hemorheology and Microcirculation
1 publication, 0.97%
|
|
|
Current Opinion in Oncology
1 publication, 0.97%
|
|
|
Future Medicinal Chemistry
1 publication, 0.97%
|
|
|
Cancers
1 publication, 0.97%
|
|
|
Pharmaceuticals
1 publication, 0.97%
|
|
|
Frontiers in Pharmacology
1 publication, 0.97%
|
|
|
Inflammopharmacology
1 publication, 0.97%
|
|
|
British Journal of Cancer
1 publication, 0.97%
|
|
|
1
2
3
|
Publishers
|
5
10
15
20
25
|
|
|
Elsevier
25 publications, 24.27%
|
|
|
Springer Nature
19 publications, 18.45%
|
|
|
Taylor & Francis
9 publications, 8.74%
|
|
|
MDPI
9 publications, 8.74%
|
|
|
Wiley
9 publications, 8.74%
|
|
|
American Chemical Society (ACS)
9 publications, 8.74%
|
|
|
American Association for Cancer Research (AACR)
5 publications, 4.85%
|
|
|
Royal Society of Chemistry (RSC)
3 publications, 2.91%
|
|
|
SAGE
2 publications, 1.94%
|
|
|
Impact Journals
2 publications, 1.94%
|
|
|
Oxford University Press
2 publications, 1.94%
|
|
|
Cold Spring Harbor Laboratory
2 publications, 1.94%
|
|
|
Bentham Science Publishers Ltd.
1 publication, 0.97%
|
|
|
IOS Press
1 publication, 0.97%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
1 publication, 0.97%
|
|
|
Frontiers Media S.A.
1 publication, 0.97%
|
|
|
IntechOpen
1 publication, 0.97%
|
|
|
Lviv Polytechnic National University
1 publication, 0.97%
|
|
|
5
10
15
20
25
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
103
Total citations:
103
Citations from 2024:
9
(8.74%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Dong Q. et al. Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer // Bioorganic and Medicinal Chemistry Letters. 2011. Vol. 21. No. 5. pp. 1315-1319.
GOST all authors (up to 50)
Copy
Dong Q. Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer // Bioorganic and Medicinal Chemistry Letters. 2011. Vol. 21. No. 5. pp. 1315-1319.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1016/j.bmcl.2011.01.071
UR - https://doi.org/10.1016/j.bmcl.2011.01.071
TI - Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer
T2 - Bioorganic and Medicinal Chemistry Letters
AU - Dong, Qing
PY - 2011
DA - 2011/03/01
PB - Elsevier
SP - 1315-1319
IS - 5
VL - 21
PMID - 21310613
SN - 0960-894X
SN - 1464-3405
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2011_Dong,
author = {Qing Dong},
title = {Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer},
journal = {Bioorganic and Medicinal Chemistry Letters},
year = {2011},
volume = {21},
publisher = {Elsevier},
month = {mar},
url = {https://doi.org/10.1016/j.bmcl.2011.01.071},
number = {5},
pages = {1315--1319},
doi = {10.1016/j.bmcl.2011.01.071}
}
Cite this
MLA
Copy
Dong, Qing, et al. “Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer.” Bioorganic and Medicinal Chemistry Letters, vol. 21, no. 5, Mar. 2011, pp. 1315-1319. https://doi.org/10.1016/j.bmcl.2011.01.071.